FWIW, CoachMarc, I'll take a stab at answering your question. The company - as admitted by press releases, SEC documents, and participation at a major venture capital conference a year ago - has been looking for an equity infusion, which they've needed because the company hadn't yet found the way to make itself profitable at roughly $6 million in annual sales. When the FDA regulations came out a couple of weeks ago, I wouldn't be all that surprised if venture capital has dried up for this industry as a whole. Accordingly, the stock has tanked, even in the midst of remarkable improvement in gross margin and restraint in expenses in recent months.
From more of a technical view - though not technical as in reading charts, as contrasted to looking at stock ownership - the recent conversions of debt into equity have left an overhang on the stock, and it may be the case that the newer shareholders via conversion are heading for the exits. I'm just throwing crap against the wall here and have no way of confirming if I'm even remotely correct.
Others on the board here may have different/better answers, but since some hours had gone by without anyone else taking a shot at answering you, I thought it would be OK for me to be batting leadoff here.
News 
Market Data 
Discover 
AI
